Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers

The need for efficacious and non-toxic cancer therapies is paramount. Oncolytic viruses (OVs) are showing great promise and are introducing new possibilities in cancer treatment with their ability to selectively infect tumor cells and trigger antitumor immune responses. Herpes Simplex Virus 1 (HSV-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Scanlan, Hayle, Coffman, Zachary, Bettencourt, Jeffrey, Shipley, Timothy, Bramblett, Debra E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364694/
https://www.ncbi.nlm.nih.gov/pubmed/35965554
http://dx.doi.org/10.3389/fonc.2022.940019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364694/
https://www.ncbi.nlm.nih.gov/pubmed/35965554
http://dx.doi.org/10.3389/fonc.2022.940019

Ejemplares similares